Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

NEW YORK – The US Food and Drug Administration announced Thursday that Cepheid's test for SARS-CoV-2, influenza, and respiratory syncytial virus received Emergency Use Authorization for use in high and moderate complexity laboratories and at the point of care. 

The rapid multiplex RT-PCR test detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus RNA and can provide results in 35 minutes. 

The test runs on the company's GeneXpert Dx and GeneXpert Infinity instruments in CLIA-certified moderate and high complexity labs and is indicated for use with nasopharyngeal and nasal swabs and nasal wash/aspirate specimens. The Xpert Xpress SARS-CoV-2/Flu/RSV test runs on the GeneXpert Xpress System at the point of care and is authorized for nasopharyngeal and nasal swabs in CLIA-waived settings.

The Danaher subsidiary announced plans to launch the multiplex test during its second quarter earnings call in July. Cepheid was the first company to receive EUA for a point-of-care test for SARS-CoV-2 in March.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.